Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Danish pharmaceutical company Lundbeck has announced a $2.6 billion deal to acquire Longboard Pharmaceuticals, gaining access to their epilepsy drug currently in late-stage development. The FDA's accelerated approval pathway has seen withdrawals and failures recently, despite having helped bring nearly 300 new drugs to market since 1992.In other news, Novo Nordisk has acquired Catalent's oral solids manufacturing facility in New Jersey, while Lilly's tirzepatide could face shortages leading to opportunities for compounders. Additionally, Pfizer has won FDA approval for a hemophilia therapy amid activist investor challenges, and Evonik is set to lay off up to 260 employees in Germany. Bluebird's gene therapy has been linked to blood cancers in children.The Institute for Cancer Research is researching preventive and regenerative medicine to extend healthy lifespan.